GSK, Am­gen and As­traZeneca tout Phase 3 da­ta in in­flam­ma­to­ry nasal con­di­tion 

GSK, Am­gen and As­traZeneca re­leased pos­i­tive da­ta sup­port­ing their ri­val drugs in a con­di­tion called chron­ic rhi­nos­i­nusi­tis with nasal polyps, or CR­SwNP.

GSK’s de­pemokimab and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER